We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.59%: What You Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed at $120.74 in the latest trading session, marking a -0.59% move from the prior day. This move was narrower than the S&P 500's daily loss of 0.77%.
Coming into today, shares of the company had lost 10.29% in the past month. In that same time, the Medical sector gained 0.02%, while the S&P 500 gained 1.55%.
Investors will be hoping for strength from CRSP as it approaches its next earnings release. The company is expected to report EPS of -$1.68, down 27.27% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $4.96 million, up 3206.67% from the prior-year quarter.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of $4.81 per share and revenue of $907.14 million. These results would represent year-over-year changes of +190.93% and +126069.07%, respectively.
Any recent changes to analyst estimates for CRSP should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. CRSP currently has a Zacks Rank of #3 (Hold).
Digging into valuation, CRSP currently has a Forward P/E ratio of 25.23. For comparison, its industry has an average Forward P/E of 25.97, which means CRSP is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 196, which puts it in the bottom 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Stock Moves -0.59%: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed at $120.74 in the latest trading session, marking a -0.59% move from the prior day. This move was narrower than the S&P 500's daily loss of 0.77%.
Coming into today, shares of the company had lost 10.29% in the past month. In that same time, the Medical sector gained 0.02%, while the S&P 500 gained 1.55%.
Investors will be hoping for strength from CRSP as it approaches its next earnings release. The company is expected to report EPS of -$1.68, down 27.27% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $4.96 million, up 3206.67% from the prior-year quarter.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of $4.81 per share and revenue of $907.14 million. These results would represent year-over-year changes of +190.93% and +126069.07%, respectively.
Any recent changes to analyst estimates for CRSP should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. CRSP currently has a Zacks Rank of #3 (Hold).
Digging into valuation, CRSP currently has a Forward P/E ratio of 25.23. For comparison, its industry has an average Forward P/E of 25.97, which means CRSP is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 196, which puts it in the bottom 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.